I read a lot of questions on multiple sclerosis (MS) social media groups from people who are worried about hair loss caused by their disease-modifying therapy (DMT). Aubagio (teriflunomide) is one DMT with a known hair loss side effect. (Fortunately, I didn’t notice any loss when I was treated with Aubgio). This real-world study, paid for by the company that markets Aubagio, should be reassuring to those Aubagio patients whose hair is thinning.
The research, “Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?,” was published in the journal Neurology and Therapy.
I hope that this Phase 3 trial moves into an approval for this treatment because I’d certainly love to have something that would improve my bladder problems. This treatment, a monthly injection of low-dose Botox, seems to be a patient-friendly way to ease such issues without some of the complications the higher dose presents.
Results from a Phase 3 clinical trial show that urinary symptoms can be reduced significantly after treatment with low-dose Botox (100 units) in patients with MS.
That finding was reported in the study “Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS,” published in the journal Neurology.
Many people with MS have reported that some medical marijuana products can help with MS spasticity and muscle cramping. A company is testing MMJ in chewing gum form. It’s working on beginning a clinical trial in Holland soon.
AXIM Biotechnologies announced that tests on its cannabinoid-based chewing gum — MedChew Rx — showed both product stability and effective release of medicinal molecules, with a high percentage of its pharmaceutical ingredients available.
It’s becoming more evident, research shows, that early treatment is a key to slowing MS progression. But, as known by many of us whose diagnosis took a long time, pinning a specific MS diagnosis can be tough. This study suggests that counting, locating, and measuring lesions on an MRI scan can do a lot to help confirm a diagnosis.
The study, “MRI in predicting conversion to multiple sclerosis within 1 year,” was published in the journal Brain and Behavior.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.